Connect
← Return to What if this prevents cancer from becoming resistant?
Discussion
What if this prevents cancer from becoming resistant?
Prostate Cancer | Last Active: 20 minutes ago | Replies (49)Comment receiving replies
@denis76 Intermittent hormone therapy was validated by the Embark study. Our oncologist suggested we read it because he is suggesting it for my husband who is Gleason 9, oligometastatic in his lymph nodes, and PSA is down to .04 on Orgovyx and Nubeqa. The results of the Embark study are promising!
Replies to "@denis76 Intermittent hormone therapy was validated by the Embark study. Our oncologist suggested we read it..."
@ucla2025 These are EMBARK's conclusions:
❝In patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus leuprolide was superior to leuprolide alone with respect to metastasis-free survival; enzalutamide monotherapy was also superior to leuprolide alone. ❞
In other words, Xtandi alone was better than Lupron alone, but both together gave the best results. They didn't test stopping both.
https://www.nejm.org/doi/full/10.1056/NEJMoa2303974
Connect
@ucla2025
I don’t know if I would call that intermittent Hormone therapy. They did not recommend stopping and starting ADT on a regular basis.
According to the studyWhen somebody had a PSA hit < .2 at 36 months they would recommend stopping the treatments. All drugs not just ADT. They then reinstated it when Prostatectomy patient hit greater than .2 and radiation treatment treatments patients PSA was greater than or equal to 5.
This actually isn’t that revolutionary. A lot of doctors will recommend their patients stop drug treatment to see what happens when their PSA becomes undetectable for a year or so.
This article discusses the exact details.
https://dailynews.ascopubs.org/do/embark-real-world-practical-tips-using-enzalutamide-high-risk-biochemical-recurrence